I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

LUND, SE / ACCESS Newswire / February 19, 2025 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.